Doctors from the University of Pennsylvania this week published an overview of current therapies available for the treatment of HCM. While this article mentions all of the old standards – beta blockers, calcium channel blockers, myectomy and alcohol ablation, the real focus is on the future of HCM treatment. In particular, the article describes several new and/or experimental therapies which look promising for the future. These include:
like mavacamten and aficamten. Two more myosin inhibitors with similar properties are currently under investigation.
The angiotensin II receptor blocker valsartan has shown promise in reducing left ventricular mass in early HCM
Novel methods of septal reduction have been used experimentally with promising results. These include:
Percutaneous septal radiofrequency ablation which uses the same radiofrequency ablation techniques previously used to treat arrhythmias to treat outflow tract obstruction.
Transcatheter myotomy which has shown promising early results in pigs and so far on one person. In this procedure, catheters and guidewires are inserted into the basal septum and electrosurgery is used to cut the heart muscle.